Advertisement
Advertisement

IPSC

IPSC logo

Century Therapeutics, Inc. Common Stock

1.72
USD
Sponsored
+0.05
+3.23%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

1.74

+0.02
+0.93%

IPSC Earnings Reports

Positive Surprise Ratio

IPSC beat 11 of 18 last estimates.

61%

Next Report

Date of Next Report
Mar 02, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.24
Implied change from Q3 25 (Revenue/ EPS)
--
/
-25.00%
Implied change from Q4 24 (Revenue/ EPS)
-100.00%
/
-44.19%

Century Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, IPSC reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.34 USD, resulting in a 7.06% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -17.54% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.24 USD, with revenue projected to reach -- USD, implying an decrease of -25.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Century Therapeutics, Inc. Common Stock reported EPS of -$0.32, beating estimates by 7.06%, and revenue of $0.00, 0% as expectations.
The stock price moved down -17.54%, changed from $0.56 before the earnings release to $0.46 the day after.
The next earning report is scheduled for Mar 02, 2026.
Based on 7 analysts, Century Therapeutics, Inc. Common Stock is expected to report EPS of -$0.24 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement